Ironwood’s shares sink as FDA demands new trial for lead drug
The FDA will require an additional Phase III trial for apraglutide, the company's candidate for short bowel syndrome.
The FDA will require an additional Phase III trial for apraglutide, the company's candidate for short bowel syndrome.
What's Your Reaction?
